FR2254344B1 - - Google Patents

Info

Publication number
FR2254344B1
FR2254344B1 FR7441101A FR7441101A FR2254344B1 FR 2254344 B1 FR2254344 B1 FR 2254344B1 FR 7441101 A FR7441101 A FR 7441101A FR 7441101 A FR7441101 A FR 7441101A FR 2254344 B1 FR2254344 B1 FR 2254344B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7441101A
Other languages
French (fr)
Other versions
FR2254344A1 (enExample
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hisamitsu Pharmaceutical Co Inc
Original Assignee
Hisamitsu Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP14055673A external-priority patent/JPS5629666B2/ja
Priority claimed from JP49024999A external-priority patent/JPS589100B2/ja
Priority claimed from JP49035325A external-priority patent/JPS5761742B2/ja
Application filed by Hisamitsu Pharmaceutical Co Inc filed Critical Hisamitsu Pharmaceutical Co Inc
Publication of FR2254344A1 publication Critical patent/FR2254344A1/fr
Application granted granted Critical
Publication of FR2254344B1 publication Critical patent/FR2254344B1/fr
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR7441101A 1973-12-14 1974-12-13 Expired FR2254344B1 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP14055673A JPS5629666B2 (enExample) 1973-12-14 1973-12-14
JP49024999A JPS589100B2 (ja) 1974-03-01 1974-03-01 シンキナ キナゾリンジオンユウドウタイ ノ セイゾウホウ
JP49035325A JPS5761742B2 (enExample) 1974-03-28 1974-03-28

Publications (2)

Publication Number Publication Date
FR2254344A1 FR2254344A1 (enExample) 1975-07-11
FR2254344B1 true FR2254344B1 (enExample) 1978-07-28

Family

ID=27284866

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7441101A Expired FR2254344B1 (enExample) 1973-12-14 1974-12-13

Country Status (5)

Country Link
US (1) US4016166A (enExample)
DE (1) DE2459090A1 (enExample)
FR (1) FR2254344B1 (enExample)
GB (1) GB1491510A (enExample)
NL (1) NL7416022A (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5271484A (en) * 1975-12-11 1977-06-14 Hisamitsu Pharmaceut Co Inc Synthesis of novel quinazoline derivatives
DE3150271A1 (de) * 1981-12-18 1983-06-30 Troponwerke GmbH & Co KG, 5000 Köln 1-(3-nitrophenyl)pyrido(2.3-d)pyrimidin-2.4(1h, 3h)-dione und 1-(3-nitrophenyl)chinazolin-2.4(1h, 3h)-dione als cutane arzneimittel
DE3347526A1 (de) * 1983-12-30 1985-07-11 Troponwerke GmbH & Co KG, 5000 Köln Verfahren zur herstellung substituierter chinazolin-2.4(1h.3h)-dione
EP0181793B1 (fr) * 1984-10-16 1988-07-27 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
CA2196510C (en) * 1996-02-01 2000-08-01 Masashi Komatsu Process for producing dioxoquinazolines
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN1856310A (zh) * 2003-09-23 2006-11-01 默克公司 喹唑啉钾通道抑制剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8765815B2 (en) * 2007-09-20 2014-07-01 Ramot At Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1059271A (en) 1964-02-05 1967-02-15 Ici Ltd Quinazolin-2,4-diones and pharmaceutical compositions thereof
NL127736C (enExample) 1964-04-20
GB1311573A (en) * 1970-04-27 1973-03-28 Hisamitsu Pharmaceutical Co Quinazolinedione derivatives
US3794643A (en) * 1971-04-20 1974-02-26 Hisamitsu Pharmaceutical Co Quinazolinedione derivatives
JPS505140A (enExample) * 1973-05-16 1975-01-20

Also Published As

Publication number Publication date
GB1491510A (en) 1977-11-09
NL7416022A (nl) 1975-06-17
US4016166A (en) 1977-04-05
DE2459090A1 (de) 1975-06-26
FR2254344A1 (enExample) 1975-07-11
AU7612574A (en) 1976-06-10

Similar Documents

Publication Publication Date Title
AR201758A1 (enExample)
AU476761B2 (enExample)
AU465372B2 (enExample)
AR201235Q (enExample)
AR201231Q (enExample)
AU474593B2 (enExample)
AU474511B2 (enExample)
AU474838B2 (enExample)
AU465453B2 (enExample)
AU471343B2 (enExample)
AU465434B2 (enExample)
AU450229B2 (enExample)
AU476714B2 (enExample)
AR201229Q (enExample)
AU466283B2 (enExample)
AR199451A1 (enExample)
AU476696B2 (enExample)
AU472848B2 (enExample)
JPS5093994A (enExample)
AU477823B2 (enExample)
AR197627A1 (enExample)
AR201432A1 (enExample)
AR200885A1 (enExample)
AR210729A1 (enExample)
AU477824B2 (enExample)

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse